BBIO
$68.54-1.58 (-2.25%)
BridgeBio Pharma, Inc., a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers.
Historical Price
Peer Comparison
Whystock Valuation Model
Fundamentals
BridgeBio Pharma, Inc., a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. The company offers Attruby, a next-generation oral ...
Recent News
Can Alnylam's Pipeline Drugs Sustain Long-Term Growth Ahead?
ALNY's strong drug sales and advancing pipeline, including late-stage candidates, are driving momentum and supporting its long-term growth outlook.
A Look At BridgeBio Pharma (BBIO) Valuation After Strong Long Term Returns And Recent Share Pullback
BridgeBio Pharma (BBIO) has drawn fresh attention after recent trading left the stock with a loss of about 8% over the past month and 7% over the past 3 months. See our latest analysis for BridgeBio Pharma. These recent pullbacks sit against a much stronger backdrop, with the share price up sharply over the past year, as reflected in a 1 year total shareholder return of 110.52% and a 3 year total shareholder return of around 4x. If this kind of biotech volatility has your attention, it could...
BridgeBio Pharma Touts Attruby Uptake, Bayer’s Europe Rollout and 2026-28 Pipeline Timelines at Leerink Conf
BridgeBio Pharma (NASDAQ:BBIO) highlighted accelerating U.S. uptake for its transthyretin (TTR) stabilizer Attruby and laid out key timelines for upcoming launches and pipeline programs during a presentation at the 2026 Leerink Partners Global Healthcare Conference. Chinmay Shukla, the company’s SVP
BridgeBio Pharma CEO Teases Pipeline Launches, Attruby Momentum, and Pfizer Tafamidis Trial Update
BridgeBio Pharma (NASDAQ:BBIO) CEO Neil Kumar discussed the company’s late-stage pipeline, commercial execution priorities, and the evolving transthyretin amyloid cardiomyopathy (ATTR-CM) market in a conversation with Barclays biotech analyst Elie Merle. Kumar also offered high-level commentary on t
BridgeBio (BBIO) Soars 13% on Double-Digit Price Target Upgrade
BridgeBio Pharma Inc. (NASDAQ:BBIO) is one of the 10 Stocks Investors Are Watching. BridgeBio saw its share prices jump by 13.22 percent on Tuesday to close at $74.32 apiece, as investors took path from an investment firm’s double-digit price target upgrade for its stock. In a market report, JPMorgan raised its price target for BridgeBio […]